• Explore /
  • Poster
  • / A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).

A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).

Abstract Poster

Authors

null

Sara M. Tolaney

Dana-Farber Cancer Institute, Boston, MA

Sara M. Tolaney , Dan G. Duda , Yves Boucher , Shom Goel , John Martin , Marek Ancukiewicz , Hannah Potler , Jaoa Incio , Jennifer A. Ligibel , Steven J. Isakoff , Dai Fukumura , Eric P. Winer , Ian E. Krop , Rakesh K. Jain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Cytotoxic Chemotherapy

Clinical Trial Registration Number

NCT00546156

Citation

J Clin Oncol 30, 2012 (suppl; abstr 1026)

DOI

10.1200/jco.2012.30.15_suppl.1026

Abstract #

1026

Poster Bd #

18

Abstract Disclosures

Similar Posters

First Author: Tarek M. A. Abdel-Fatah

First Author: Naoko Matsuda

First Author: Elisavet Paplomata

First Author: Antoinette R. Tan